Under the treatment with BRAF inhibitors or MEK inhibitors, tumor cells including melanoma finally adapt to drug treatment by upregulation of autophagy (Martin et al., 2017; Mulcahy Levy et al., 2017), suggesting the availability of autophagy inhibitors in combination with targeted therapies. Here, BRAF is linked to neoplasm.